46 results about "Cardiac rhythm disturbances" patented technology

Methods and systems for endovascular, endocardiac, or endoluminal approaches to a patient's heart to perform surgical procedures that may be performed or used without requiring extracorporeal cardiopulmonary bypass. Furthermore, these procedures can be performed through a relatively small number of small incisions. These procedures may illustratively include heart valve implantation, heart valve repair, resection of a diseased heart valve, replacement of a heart valve, repair of a ventricular aneurysm, repair of an arrhythmia, repair of an aortic dissection, etc. Such minimally invasive procedures are preferably performed transapically (i.e., through the heart muscle at its left or right ventricular apex).

A catheter for treating arrhythmia comprises a catheter shaft of a double-cylinder structure where an inner shaft is slidably inserted in an outer shaft, a balloon installed so as to straddle between the tip portion of the inner shaft and the tip portion of the outer shaft, a pair of high frequency current-carrying electrodes of which at least one electrode is provided inside the balloon, and a temperature sensor for monitoring the temperature in the balloon. The front edge portion of the balloon at least in a deflated state protrude from the tip portion of the inner shaft. Alternatively, a tube that is more flexible than the inner shaft is provided on the tip portion of the inner shaft.

A catheter apparatus is provided for use in the treatment of heart arrhythmia having a catheter shaft, a mapping and ablation catheter disposed within the shaft, and a control mechanism coupled to both the shaft and catheter. The catheter shaft includes a main body and a coaxial tip section joined to the main body. The tip section can be rotated about a central axis and curved away from the central axis in a controlled manner. The mapping and ablation catheter can be extended outward from the catheter shaft where it is able to take the form of a pre-stressed curve. The control mechanism controls axial rotation of the tip section, the degree of deflection of the tip section and longitudinal movement of the mapping and ablation catheter with respect to the catheter shaft. Preferably, the mapping and ablation catheter forms a pre-stressed loop when it is fully extended from the catheter shaft.In another aspect of this invention, it provides a method for treatment of a heart arrhythmia having the steps of (1) obtaining cardiac image data from a medical imaging system, (2) creating a 3D model from this cardiac image data, (3) registering the 3D model to an interventional system, (4) positioning a catheter apparatus within a chamber of the heart, (5) displaying the catheter apparatus over the registered 3D model on the interventional system, (6) navigating the catheter apparatus within the heart guided by the registered 3D model, and (7) having the catheter apparatus ablate heart tissue at select locations.

A catheter for treating arrhythmia comprises a catheter shaft of a double-cylinder structure where an inner shaft is slidably inserted in an outer shaft, a balloon installed so as to straddle between the tip portion of the inner shaft and the tip portion of the outer shaft, a pair of high frequency current-carrying electrodes of which at least one electrode is provided inside the balloon, and a temperature sensor for monitoring the temperature in the balloon. The front edge portion of the balloon at least in a deflated state protrude from the tip portion of the inner shaft. Alternatively, a tube that is more flexible than the inner shaft is provided on the tip portion of the inner shaft.

A method discriminates between ventricular arrhythmia and supraventricular arrhythmia by determining the direction of an electrical signal conducted through the atrioventricular node. An implantable cardiac defibrillator provides atrioventricular and ventriculoatrial pacing bursts to determine if an arrhythmia with a 1:1 atrial to ventricular relationship is due to ventricular tachycardia or supraventricular tachycardia. This discrimination capability reduces the incidence of inappropriate shocks from dual-chamber implantable cardiac defibrillators to near zero and provides a method to differentially diagnose supraventricular tachycardia from ventricular tachycardia.

In an implantable pacemaker, pacing pulses are delivered to a ventricle in a P-wave synchronous mode as long as no atrial arrhythmia is detected, pacing pulses and a mode switch is made to deliver pacing pulses to the ventricle in a non-P-wave synchronous mode if atrial arrhythmia is detected. From an impedance signal measured in the atrium, atrial distention is determined and, in the non-P-wave synchronous mode, the delivery rate of the pacing pulses is increased to decrease the atrial distention during atrial arrhythmia.

The invention relates to medicine, namely to cardiology, cardiovascular surgery, functional diagnosis and clinical electrophysiology of the heart. The invention consists in reconstructing electrograms, whose experimental registration requires an invasive access, by computational way on unipolar ECGs recorded at 80 and more points of the chest surface. Based on reconstructed electrograms, isopotential, isochronous maps on realistic models of the heart are constructed, the dynamics of the myocardium excitation is reconstructed and electrophysiological processes in the cardiac muscle are diagnosed. Application of the method allows one to improve the accuracy of non-invasive diagnosis of cardiac rhythm disturbances and other cardio-vascular diseases.

A method for operating a cardiac pacemaker in which the mode of operation of the pacemaker is altered in response to detecting an episode of atrial tachycardia. In accordance with the invention, the pacemaker's pacing mode is altered in a manner that attempts to maintain hemodynamic stability during the atrial tachycardia. Such a mode switch is particularly applicable to pacemaker patients suffering from some degree of congestive heart failure.

A system and method are provided for discriminating supra-ventricular tachycardia (SVT) from ventricular tachycardia (VT). A monitoring EGM signal is acquired during a sensing window timed according to the time of R-wave detection on a reference EGM signal. A normal sinus rhythm (NSR) template is generated using the monitoring EGM signal during the time-referenced sensing window. During an unknown rhythm, the monitoring EGM signal sensed during the time-referenced sensing window is compared to the NSR template for use in computing a morphology metric. The morphology metric is compared to a VT / VF detection threshold for discriminating SVT from VT / VF.

A system and method are provided for discriminating supra-ventricular tachycardia (SVT) from ventricular tachycardia (VT). A monitoring EGM signal is acquired during a sensing window timed according to the time of R-wave detection on a reference EGM signal. A normal sinus rhythm (NSR) template is generated using the monitoring EGM signal during the time-referenced sensing window. During an unknown rhythm, the monitoring EGM signal sensed during the time-referenced sensing window is compared to the NSR template for use in computing a morphology metric. The morphology metric is compared to a VT / VF detection threshold for discriminating SVT from VT / VF.

A catheter for treating irregular heart pulse comprises a catheter shaft of a double-cylinder structure where an inner cylinder shaft is slidably inserted in an outer cylinder shaft, a balloon installed so as to straddle between the tip portion of the inner cylinder shaft and the tip portion of the outer cylinder shaft, a pair of high frequency current-carrying electrodes of which at least one electrode is provided inside the balloon, and a temperature sensor for monitoring the temperature in the balloon. The front edge portion of the balloon at least in a deflated state is projected to more forward than the tip portion of the inner cylinder shaft. Alternatively, a tube that is more flexible than the inner cylinder shaft is provided on the tip portion of the inner cylinder shaft.

An implantable cardiac device is provided for adaptive ventricular rate smoothing during atrial fibrillation (AF). When AF is detected, the operation of the device is switched to non-atrial synchronized pacing mode such as DDI, DDIR, VDI, VDIR, VVI, or VVIR. The ventricular escape interval (VEI) is beat-by-beat modulated around a physiological interval zone (PIZ), which is determined by the pre-arrhythmia ventricular rate or the output of rate responsive sensor. The VEI remains unchanged if the preceding ventricular event is sensed and its RR interval is within the PIZ. Otherwise, the VEI is decreased asymptotically toward a lower interval threshold if the preceding RR interval is longer than the upper limit of the PIZ, or the VEI is increased asymptotically toward an upper interval threshold if the preceding RR interval is shorter than the upper limit of the PIZ. The step of incrementing or decrementing the VEI is adaptive to the absolute difference value between the preceding RR interval and the asymptotic interval threshold to ensure fast recovery of deviant RR interval toward the PIZ and to reduce the amount of high rate ventricular paces after a ventricular sense with very short coupling interval.

A method for operating a cardiac pacemaker in which the mode of operation of the pacemaker is altered in response to detecting an episode of atrial tachycardia. In accordance with the invention, the pacemaker's pacing mode is altered in a manner that attempts to maintain hemodynamic stability during the atrial tachycardia. Such a mode switch is particularly applicable to pacemaker patients suffering from some degree of congestive heart failure.

An implantable cardiac device is provided for adaptive ventricular rate smoothing during atrial fibrillation (AF). When AF is detected, the operation of the device is switched to non-atrial synchronized pacing mode such as DDI, DDIR, VDI, VDIR, VVI, or VVIR. The ventricular escape interval (VEI) is beat-by-beat modulated around a physiological interval zone (PIZ), which is determined by the pre-arrhythmia ventricular rate or the output of rate responsive sensor. The VEI remains unchanged if the preceding ventricular event is sensed and its RR interval is within the PIZ. Otherwise, the VEI is decreased asymptotically toward a lower interval threshold if the preceding RR interval is longer than the upper limit of the PIZ, or the VEI is increased asymptotically toward an upper interval threshold if the preceding RR interval is shorter than the upper limit of the PIZ. The step of incrementing or decrementing the VEI is adaptive to the absolute difference value between the preceding RR interval and the asymptotic interval threshold to ensure fast recovery of deviant RR interval toward the PIZ and to reduce the amount of high rate ventricular paces after a ventricular sense with very short coupling interval.

A method and system for operating a cardiac rhythm management device which employs pacing therapy to regularize the ventricular rhythm. Such ventricular rate regularization may be employed with conventional bradycardia pacing, ventricular resynchronization therapy, or anti-tachyarrhythmia therapy.

This document describes systems, devices, and methods that use multiple morphology templates for discriminating between rhythms, such as supraventricular tachyarrhythmias (SVTs) and ventricular tachyarrhythmias (VTs), for delivering a countershock in response to a VT episode, but withholding delivery of such a countershock in response to an SVT episode. In certain examples, the particular morphology used for storing morphological features is selected at least in part using a sensor-indicated activity level of a subject, or a metabolic need of the subject.

A method for operating a cardiac pacemaker in which the mode of operation of the pacemaker is altered in response to detecting an episode of atrial tachycardia. In accordance with the invention, the pacemaker's pacing mode is altered in a manner that attempts to maintain hemodynamic stability during the atrial tachycardia. Such a mode switch is particularly applicable to pacemaker patients suffering from some degree of congestive heart failure.

The invention relates to medicine, namely to cardiology, cardiovascular surgery, functional diagnosis and clinical electrophysiology of the heart. The invention consists in reconstructing electrograms, whose experimental registration requires an invasive access, by computational way on unipolar ECGs recorded at 80 and more points of the chest surface. An application of the method allows one to improve the accuracy of non-invasive diagnosis of cardiac rhythm disturbances and other cardio-vascular diseases.

The invention relates to medicine, namely to cardiology, cardiovascular surgery, functional diagnosis and clinical electrophysiology of the heart. The invention consists in reconstructing electrograms, whose experimental registration requires an invasive access, by computational way on unipolar ECGs recorded at 80 and more points of the chest surface. Based on reconstructed electrograms, isopotential, isochronous maps on realistic models of the heart are constructed, the dynamics of the myocardium excitation is reconstructed and electrophysiological processes in the cardiac muscle are diagnosed. Application of the method allows one to improve the accuracy of non-invasive diagnosis of cardiac rhythm disturbances and other cardio-vascular diseases.

A method for operating a cardiac pacemaker in which the mode of operation of the pacemaker is altered in response to detecting an episode of atrial tachycardia. In accordance with the invention, the pacemaker's pacing mode is altered in a manner that attempts to maintain hemodynamic stability during the atrial tachycardia. Such a mode switch is particularly applicable to pacemaker patients suffering from some degree of congestive heart failure.

The composition of Chinese medicine effective parts for treating cardiac and cerebral vascular diseases consists of general salvianolic acid and general astragalus saponin in certain ratio. The compound medicine has raised pharmacological effect and clinical curative effect and reduced impurity content. It may be prepared into various preparation forms. It is used in treating coronary heart disease, angina pectoris, myocardial ischemia, heart failure, arrhythmia, cerebral infarction and cerebral ischemia; and is safe, effective stable, controllable and convenient.

In one embodiment, a wearable defibrillation system may sense whether its wearer meets an unconscious bradyarrhythmia condition that can be associated with becoming unconscious. Even though such a condition might not be helped with a defibrillation pulse, the wearable-defibrillation system may still administer pacing pulses to prevent the bradycardia from becoming worse, such as a sudden cardiac arrest. In some embodiments, the pacing pulses are administered at a frequency too slow for the patient to regain consciousness. An advantage is that, because the patient remains unconscious, he does not experience the sometimes severe discomfort due to the pacing pulses.

The invention relates to medicine, namely to cardiology, cardiovascular surgery, functional diagnosis and clinical electrophysiology of the heart. The invention consists in reconstructing electrograms, whose experimental registration requires an invasive access, by computational way on unipolar ECGs recorded at 80 and more points of the chest surface. An application of the method allows one to improve the accuracy of non-invasive diagnosis of cardiac rhythm disturbances and other cardio-vascular diseases.

The invention provides a pyrolytic diterpenoid alkaloid compound shown as a formula I shown in the specification, or a salt, a stereoisomer or a solvate thereof, and a preparation method of the pyrolytic diterpenoid alkaloid compound. The invention also provides application of the compound or the salt thereof, the stereoisomer thereof or the solvate thereof in preparing medicines for preventing and / or treating ventricular premature beat, ventricular tachycardia and antiarrhythmia, and the clinical prospect is excellent.